We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
- Authors
Scaltriti, Maurizio; Rojo, Federico; Ocaña, Alberto; Anido, Judit; Guzman, Marta; Cortes, Javier; Di Cosimo, Serena; Matias-Guiu, Xavier; Ramon y Cajal, Santiago; Arribas, Joaquin; Baselga, José
- Abstract
Women with HER2-overexpressing breast cancers have poor prognosis, and many are resistant to the HER2 monoclonal antibody trastuzumab. A subgroup of HER2-overexpressing tumors also express p95HER2, an amino terminally truncated receptor that has kinase activity. Because p95HER2 cannot bind to trastuzumab but should be responsive to the HER2 tyrosine kinase inhibitor lapatinib, we compared the sensitivity of tumors expressing p95HER2 and tumors expressing the full-length HER2 receptor to these agents.
- Publication
Journal of the National Cancer Institute, 2007, Vol 99, Issue 8, p628
- ISSN
1460-2105
- Publication type
Journal Article
- DOI
10.1093/jnci/djk134